Investment

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

This week in Drug Discovery (27 April – 1 May) 

News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW.  This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More

#News

Great British Pounds, Investment
#BioIndustry Association #Europe #Investment #UK

UK leads European biotech investment, BIA reports 

UK biotech led investment in the European market in the first quarter of 2026, new figures from the BioIndustry Association (BIA) show.  The BIA report shows renewed financing was driven by a rebound in venture capital investment and a broader distribution of funding across companies and stages. … Read More

#News

Soft tissue sarcoma
#Investment #Sarcoma #Storm Therapeutics

STORM secures $56m financing for sarcoma treatment 

Biotechnology company STORM Therapeutics has announced it has secured $56 million in a Series C financing to support its sarcoma treatment.  The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3. This extends to funding the company’s Phase II monotherapy study… Read More

#Business & Investment #News

#BioTrinity #Investment #MHRA #Regulatory #UK

Key takes from BioTrinity 2026

DDW Editor Reece Armstrong attended day one of BioTrinity. Here he offers an overview of the conference and the themes to come out of it.   In an era of turbulence, BioTrinity stood out with an air of general positivity concerning the UK’s current standing within the life… Read More

#Business & Investment #Exclusive Content

#Concussion #Investment #Oxeia Biopharmaceuticals

Oxeia surpasses funding goal for concussion therapy 

Biotech company Oxeia Biopharmaceuticals has announced its first crowdfunding campaign was oversubscribed, raising over $1.2 million before its scheduled close.  The company, which develops concussion therapeutics, has surpassed its crowdfunding goal, reflecting interest in its clinical-stage ghrelin therapy for persistent concussion symptoms.  The therapy, OXE103, demonstrated an 85%… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Biotech #Drug development #Investment #Market reporting

Treehill Partners: Reflections on JPM and trends for 2026  

DDW Editor Reece Armstrong speaks to Ali Pashazadeh, CEO of capital market company Treehill Partners, about how his experience of this year’s JPM reflects how the industry will move forward in 2026.   The beginning of a new year in drug discovery and development is always marked with the arrival of the JP Morgan Healthcare… Read More

#Business & Investment #Exclusive Content

#Artificial intelligence (AI) #Drug discovery #Investment #Machine learning

Pharmacelera raises $6m to advance AI drug discovery  

Deep tech company Pharmacelera has raised $6 million in an investment round to help accelerate its expansion in the United States and grow its platform.   Pharmacelera uses its proprietary quantum mechanics and artificial intelligence (QaiM) algorithms to find novel and diverse molecular candidates across the chemical “exaSpace”.   The company says its algorithms can generate… Read More

#News

Map of China
#AstraZeneca #China #Investment #Obesity #Weight loss

AZ expands China operations, agrees obesity deal with CSPC

AstraZeneca has agreed a new strategic collaboration agreement with China’s CSPC Pharmaceuticals to develop multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.   Under this agreement, the companies will initially progress four programmes, which utilise CSPC’s AI-driven peptide drug discovery platform and its LiquidGel… Read More

#Business & Investment #News #Trending News

#GlobalData #Investment #Pharmaceutical industry #Politics #Tariffs #UK #United States

Is US foreign policy uncertainty strengthening confidence in the UK?

The recent UK-US policy developments are reshaping global pharmaceutical investment and launch strategies, according to intelligence platform GlobalData.  In December 2025, the UK announced a landmark pharmaceuticals agreement with the US, granting UK-made medicines and medical technologies tariff-free access to the US market for… Read More

#Business & Investment #News #Trending News

#Biotech #Financing #Investment

$100m fund set up to invest in biotech companies 

Investment manager Arkin Capital has closed a $100 million financing round to set up Arkin Bio Ventures III, a $100m fund aimed at investing in biotech companies.  Arkin Bio Ventures III will back 10 to 12 pre-clinical to early clinical-stage biotech companies, developing transformative therapies in areas… Read More

#Business & Investment #News

#Advanced Therapies #Cell and gene therapy #GlobalData #Investment

Investment shifting in cell and gene therapy, report reveals 

Tighter budgets and company acquisitions have altered investment in the cell and gene therapy (CGT) sector, new analysis finds.  According to a report from data and analytics company GlobalData, the CGT sector is transitioning as companies navigate a more selective and strategy-driven funding landscape.  While venture… Read More

#Business & Investment #News

Tower Bridge, London
#Drug discovery #Events #Investment #London Life Sciences Week #Market reporting

‘Good vibrations’ at London Life Science Week bode well for 2026

Jefferies’ Global Healthcare Conference held every November and coinciding with London Life Science Week (LLSW), is staking its claim as one of the world’s ‘must attend’ biotech investor events – and a vital barometer going into the New Year. DDW found the atmosphere refreshingly upbeat.  “Going into… Read More

#Exclusive Content #Trends & Analysis